The combination of lincomycin and spectinomycin has an additive mode of action, and in many cases acts synergistic. Lincomycin has a bacteriostatical mode of action against mainly Gram-positive bacteria (like Staphylococcus aureus, Streptococcus pyogenes, Str. suis, Str. agalactia, Diplococcus pneumonia, Corynebacterium pyogenes, Clostridium perfringens, Cl. tetani and Pasteurella multocida). Enterococci and Gram-negative bacteria are hardly sensitive. Anaerobe micro-organisms are very sensitive, like Bacteroides spp. and Fusibacterium spp. (Doyle-dysentery) and Mycoplasmas (like M. galli septicum, M. hyosynovia, M. meleagridis, M. canis and M. hyorhinis; M. pneumonia is hardly sensitive).
Spectinomycin has a broad bacteriostatical spectrum. Sensitive for spectinomycin are especially the Gram-negative and some Gram-positive bacteria (like Aerobacter aerogenes, E. coli, Klebsiella pneumonia, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella spp., Vibrio coli and Diplococcus pneumonia). Furthermore spectinomycin is active against Mycoplasmas (like M. gallisepticum, M. meleagridis and M. synvia). Cross-resistance of lincomycin with erythromycin and other macrolides is rule.